Pulmonary Vascular Resistance Abnormality
7
1
2
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (7)
ET1 Concentration, Metabolic Pathway Activation, and Pulmonary Blood Flow in Infants Undergoing Superior Cavo-Pulmonary Anastomosis
Treatment of Pulmonary Hypertension in High-risk Cardiac Surgery Patients Using Inhalational and Intravenous Agents
Mechanisms of Pulmonary Vascular Dysfunction in Heart Failure
PV Loop and Pulmonary Hypertension
Levosimendan Administration in Pulmonary Hypertension
Iron Status and Cardiopulmonary Physiology
Beta3 Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure